News & events

Press releases

5 May 2022, Sophia-Antipolis, France

Median Technologies is moving forward with the FDA interactions for its iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device

Median has received the FDA’s feedback following the 513(g) regulatory submission for its iBiopsy® LCS CADe/CADx Software as Medical Device. Median will proceed through a 510(k) submission to obtain an FDA device clearance and market authorization, targeted for end 2023. On May 2, 2022, Median initiated a Q-submission process, composed of several submissions, to request feedback from the FDA on various topics such as the pivotal study protocols.

Read more
See all press releases


3 - 7 June, 2021 | McCormick Place, Chicago, IL, USA

ASCO 2022

Median will be exhibiting at the 2022 ASCO Annual Meeting, which will take place from June 3 to June 7 in Chicago, IL.  Stop by our booth #2098 to learn more about our breakthrough imaging solutions and services for oncology clinical trials. Happy to see you there during the whole exhibition duration, from June 4 to 6.

Visit conference website
See all conferences

In the press

iBiopsy® for Precision Medicine

Check out our paper published in the European Medical Journal on December 13, 2018 in order to educate the oncology specialists across Europe and the US as to the high-throughput artificial intelligence powered image-base phenotyping platform, iBiopsy® ->


A high-throughput artificial intelligence-powered image-based phenotyping platform, iBiopsy® (Median Technologies, Valbonne, France), which aims to improve precision medicine, is discussed in the presented review. The article introduces novel concepts, including high-throughput, fully automated imaging biomarker extraction; unsupervised predictive learning; large-scale content-based image-based similarity search; the use of large-scale clinical data registries; and cloud-based big data analytics to the problems of disease subtyping and treatment planning. Unlike electronic health record-based approaches, which lack the detailed radiological, pathological, genomic, and molecular data necessary for accurate prediction, iBiopsy® generates unique signatures as fingerprints of disease and tumor subtypes from target images. These signatures are then merged with any additional omics data and matched against a large-scale reference registry of deeply phenotyped patients. Initial applications targeted include hepatocellular carcinoma and other chronic liver diseases, such as nonalcoholic steatohepatitis. This new disruptive technology is expected to lead to the identification of appropriate therapies targeting specific molecular pathways involved in the detected phenotypes to bring personalised treatment to patients, taking into account individual biological variability, which is the principal aim of precision medicine.

See all in the press


See all blog entries


JUNE 21st, 2022

Overcoming the challenges in deploying new imaging biomarkers in clinical trials – Perspectives from patients, physicians and other stakeholders

This webinar is jointly organized by Labcorp Drug Development and Median Technologies. New Imaging biomarkers have a strong potential to provide additional insight for clinical trials: better selection of patients, prediction of response to therapy, early assessments of drug effects and safety. However, implementing them in clinical trials often promote challenges. The aim of this webinar is to discuss these challenges from the perspective of patients, physicians and the different stakeholders involved in the oncology clinical trials. During this webinar, you will learn:

  • The value of modern imaging technologies in oncology trials
  • The challenges linked to implementation of new imaging biomarkers
  • How AI powered imaging optimizes clinical trial design


  • Dr Yumin Zhang, Vice President and Chief Medical Officer, Huayi Technology CO LTD
  • Dr Ravi Karra, M.D, Senior Medical Director Oncology, Labcorp Drug Development
  • Dr Yan Liu, Chief Medical Officer, Median Technologies.
See all webinars